pis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MULN still going - I picked up some at .95 earlier but sold them - still have a few at 1.13 jic
MULN nice bounce
I sold about 500 F when it spiked and got in the 20's. I have about half that amount still and was planning on rebuying what I sold on a dip. I wanted under 15, but I don't think it did that. If it did I missed it.
EV's aren't going away - they may have run up hugely but they are the future. Look at MULN and how far that one fell.
Haven't traded RIVN since it was over 100 bucks. Can't believe how low it has slipped. Those new issues are tough to calculate since they have no price history. I guess if you are a long term holder it is attractive here. Supply chain problems has hit this co.
now down 32% - just bought a few here - looks like it may be a low floater - did not buy a lot
MYO down 26% earnings
SBFM down 35% on offering Company will issue 3,603,604 units at a purchase price of $2.22
Another 8k just filed: https://www.otcmarkets.com/filing/html?id=15647431&guid=6jHwkKH-nw8WJth
On or about February 8, 2022, we incorporated Next Meats HK Co. Limited, a Hong Kong Company. Next Meats HK Co. Limited is now a wholly owned subsidiary of the Company. The Registry Number associated with this entity in Hong Kong is 3126390.
On or about March 2, 2022, we incorporated Next Meats (S) Pte. Ltd., a Singapore Company. Next Meats (S) Pte. Ltd. is now a wholly owned subsidiary of the Company. The Company Registration Number in Singapore is 202207295H.
Although our future plans are not clearly defined in regards to the above subsidiaries, and while any such plans may change in time, at present we intend to utilize both of the above entities to expand our global reach of selling alternative meat products throughout Asia.
Yep. Those chocolate covered donuts you put in the frig are the ONLY donuts I ever really liked. Haven't had one in years so don't know if they are still made that well. Do you get Entenmann down by you?
did a quick flip on that - 1.13 to 1.25
USWS look out - down 36% - offering purchase price of $1.763 per share
I'm not a man - at least last time I checked. Please relax and get yourself a drink.
What is your point? Is it to annoy? Because you have accomplished that - congrats to you. Now go yell "fire" into a different theater.
nice call on sntg Mark
feel better
AYRO starting to come back- volume increasing 1.42
They had some type of tsla agreement back in June - I haven't heard of anything new
Holy cow, Batman! Good call on ensv!!! WTG
...and there it goes! sbsw
Yeah, 10% down may sound like nothing and I don't really post them as bouncers unless they went up a lot like this one did - it is an metals play
but it is 4.11 now in premarket lol
52 week low? that was 2.41
SBSW down 10% premarket - metals co giving back some
Me too - back in MULN at .98
VRM down 42% earnings - looks a bit overdone here - got a few at 3.51
MULN down 32% after huge move up yesterday
GDRX down 40% - terrible earnings report
ENVB up 46% but still under that offering price from last month
ENVB up 42%
RSX at the lowest price seen during regular-session hours since March 2009 Will probably go even lower!!
especially on failed drug news or offerings
KOD down 79% Shares of Kodiak Sciences Inc. (KOD) plummeted 76.3% to pace all premarket decliners Wednesday, after the biopharmaceutical company said a Phase 2b/3 trial of its treatment for age-related macular degeneration failed to meet its primary efficacy endpoint. The selloff put the stock on track to open at the lowest price seen during regular-session hours since September 2019. The company said its KSI-301 showed "strong durability," and was safe and well tolerated, but it did not meet the primary endpoint of showing "non-inferior visual acuity gains" for those dosed on extended regimens compared with aflibercept given every eight weeks. "We learned that the study design stretched it too far for the roughly 30% of patients who could have benefited from more VEGF inhibition than the minimal every 3 months in the study," said Dr. Carl Regillo, Chief of the Retina Service at Wills Eye Hospital in Philadelphia. The stock had already plunged 48.6% over the past three months through Tuesday, while the iShares Biotechnology ETF (IBB) has slumped 18.9% and the S&P 500 has lost 8.2%.
SAGE now down 15% Wall Street raised questions about the durability of the experimental treatment for major depressive disorder that Sage is developing with Biogen Inc. .
SAGE down 10% on this news? Sage's depression drug meets main goal in late-stage study
Oh, I thought you were talking about figure skating. I was picturing you practicing your double axel.
ENVB is down on offering priced at .50 - offering plays aren't what they used to be - the other one I don't know about
out again 1.49
I flipped it 1.48 to 1.57 earlier and just bought again 1.41